PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23089750-7	2013	Time-dependent killing of ceftazidime was observed in PAO1 biofilms, but concentration-dependent killing activity of ceftazidime was observed for beta-lactamase-overproducing biofilms of P. aeruginosa in all three models.	Ceftazidime	117-128	beta-lactamase	Pseudomonas aeruginosa PAO1	146-160	
23089750-13	2013	The inoculum effect of ceftazidime for the beta-lactamase-overproducing mutant PADeltaDDh2Dh3 biofilms was more obvious than for PAO1 biofilms, with a requirement of higher antibiotic concentration and a longer period of treatment.	Ceftazidime	23-34	beta-lactamase	Pseudomonas aeruginosa PAO1	43-57	
32660987-3	2020	Recently, a number of clinical isolates expressing mutated forms of AmpC have been found to be clinically resistant to the antipseudomonal beta-lactam/beta-lactamase inhibitor (BLI) combinations ceftolozane/tazobactam and ceftazidime/avibactam.	Ceftazidime	222-233	beta-lactamase	Pseudomonas aeruginosa PAO1	68-72	
32660987-10	2020	It is remarkable that these mutations enhance the catalytic efficiency of AmpC towards ceftolozane and ceftazidime while simultaneously reducing susceptibility to inhibition by avibactam.	Ceftazidime	103-114	beta-lactamase	Pseudomonas aeruginosa PAO1	74-78